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Abstract B cell dyscrasias are often refractory to medical
treatments, and hematological stem cell therapy (SCT) may
be warranted. It is not clear whether an associated poly-
neuropathy may also profit from SCT. In exceptional cases
SCT has been tried in patients with monoclonal gammop-
athy and progressive polyneuropathy refractory to medical
treatments. In a cohort of 225 patients with monoclonal
gammopathy and polyneuropathy, we selected the six
patients who underwent SCT and retrospectively examined
the effects of SCT on the disease course of the associated
polyneuropathy. In all patients except one, the indication
for SCT was hemato-oncological (multiple myeloma in 4
patients and primary AL amyloidosis in 1). The remaining
patient had an IgG monoclonal gammopathy of undeter-
mined significance and a progressive and painful poly-
neuropathy for which she was treated with SCT. SCT led to
improvement of motor scores and autonomic symptoms in
one patient; three patients experienced improvement of
neuropathic pain or sensory deficits but showed further
progression of weakness. One patient showed no
improvement at all. One patient died within 100 days after
SCT. In conclusion, SCT as a treatment of refractory
hematological malignancy may occasionally have a posi-
tive effect on the associated progressive polyneuropathy,
although the benefits are very limited and the treatment-
related mortality is high.
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Introduction
B cell dyscrasias are associated with polyneuropathies. A
variety of pathogenetic mechanisms, including cytokine-
mediated damage, nerve infiltration, synthesis and deposi-
tion of noxious monoclonal proteins or binding of mono-
clonal antibodies to nerve constituents, may cause
neuropathy in patients with B cell disorders. The disease
course of these polyneuropathies may be mild, but can also
be very debilitating, causing severe sensorimotor deficits
and autonomic dysfunction [1, 2].
Unfortunately, polyneuropathy associated with mono-
clonal gammopathy is often refractory to treatment. Intra-
venous immunoglobulins (IVIg) and the anti-CD20
monoclonal antibody rituximab may ameliorate the disease
course in a minority of patients [3, 4]. Hematological stem
cell therapy (SCT) is a well-established therapy used for
refractory hematological malignancies. SCT has been
reported to attenuate the progressive disease course of
patients with polyneuropathy with organomegaly, endo-
crinopathy, M-protein and skin changes (POEMS) [5, 6],
chronic inflammatory demyelinating polyneuropathy
(CIDP) [7, 8], primary AL amyloidosis [9], and recently in
a small series of patients with IgG MGUS- or MM-asso-
ciated neuropathy [10], but it is unknown whether SCT
may represent a rescue therapy for a wider range of patients
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with polyneuropathy and B cell dyscrasias and whether the
possible beneficial effects outweigh risks associated with
SCT.
Here we describe six patients with malignancy-associ-
ated polyneuropathy receiving SCT primarily for the
treatment of their hematological disorders and report on the
effects on the neuropathy.
Patients and methods
Patient characteristics
Six patients (2.7%) from a cohort of 225 patients [11] with
polyneuropathy and B cell dyscrasia underwent SCT. The
primary indication for SCT was the hematological malig-
nancy in all patients with the exception of patient 5, in
whom improvement of the polyneuropathy was the main
goal. Clinical data and data from nerve conduction studies
were collected prospectively following a standardized
protocol that has been in use for this patient group since
1985. These data were analyzed retrospectively to asses the
effect of SCT on the course of the polyneuropathy. Patient
characteristics are summarized in Table 1. All patients
presented with complaints consistent with polyneuropathy,
with B cell dyscrasia found during the neuropathy work-up.
Four patients had multiple myeloma (MM) unresponsive to
other treatments (patients 1, 2, 3 and 6), one had light chain
(AL) amyloidosis, and one patient had an IgG MGUS and a
rapidly progressive demyelinating polyneuropathy despite
treatment with IVIg and glucocorticosteroids (patient 5).
With the exception of patient 1, who had a monozygous
twin brother who acted as a donor, all patients were
treated with autologous SCT. All transplantations were
carried out in the Utrecht Medical Center, a tertiary
referral center for hemato-oncology and (autologous)
stem cell transplantation. Institutional morbidity and
mortality lie well within international standards, as pub-
lished elsewhere (10% treatment related mortality in MM
patients) [11].
Neurological examinations before and 1 year after stem
cell transplantation were performed using a standardized
protocol, described elsewhere [12]. Motor function was
expressed using the Modified Medical Research Council
(MRC) motor sum score of 14 muscle groups in both arms
and legs, with a maximum score of 140 points. Sensory
function was expressed as a sensory composite sum score
consisting of scores for sense of touch (0–4), pain (0–4)
and vibration (0–4) in both arms and legs, and position
sense (0–2) in both legs with a maximum of 56 points
[12]. The modified Rankin score, (ranging from 0 for no
symptoms at all to 5 for severely disabled and bedrid-
den and 6 for dead) was used to quantify functional
disability.
All patients underwent systematic nerve conduction
studies using a previously described protocol [12]. Demy-
elination was defined according to previously established
criteria. Nerve conduction studies that showed a reduction
of CMAP amplitudes to less than 20% of normal values in
at least two nerves but did not meet the criteria for
demyelination were scored as axonal [13].
Other causes of polyneuropathy than monoclonal gam-
mopathy were excluded following a standardized protocol
[12].
Table 1 Patients’ age at first visit in our neuromuscular clinic, paraprotein, hematological diagnosis and predominant clinical manifestation of
the polyneuropathy






Rankin score Clinical effect of SCT
on polyneuropathy
Before After Before After Before After
1 44 IgAk Multiple
myeloma
Motor 122 137 54 56 2 2 Improvement
2 60 IgAk Multiple
myeloma
Sensorimotor 132 128 44 40 2 2 Stabilization
3 59 IgGj Multiple
myeloma
Sensorimotor 108 (*) 24 (*) 3 (*) Rapid further progression,
death




140 137 46 44 3 2 Improvement in autonomic
neuropathy
5 58 IgGk MGUS Sensorimotor 112 110 27 31 4 4 Stabilization
6 48 IgDk Multiple
myeloma
Sensorimotor 138 136 50 50 2 2 Stabilization
Motor sum score, sensory sum score, modified ranking score, before and after treatment. Overall clinical result. (*) died before 1 year follow-up
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Case histories and results (Table 1)
Patient 1 was diagnosed with MM with IgA monoclonal
gammopathy and had a progressive, predominantly motor
neuropathy, with severe weakness, hypesthesia and pares-
thesia in the lower legs and hypesthesia in the fingertips.
Nerve conduction studies showed distal demyelinisation in
arms and legs. He was first treated with melfalan and dexa-
methasone and then, after pre-treatment with cyclophos-
phamide and total body irradiation, underwent allogenic
stem cell transplantation with stem cells from his HLA-
identical twin brother 18 months after the first manifestation
of polyneuropathy. SCT was complicated by mild graft
versus host disease. One year after transplantation, strength
in his legs had virtually normalized (MRC motor sum score
improved from 122 to 137 out of 140).
Neurological deficits further improved slightly in the
second year after SCT and then remained unchanged until
11 years after transplantation, when an exacerbation of
MM was preceded by progression of sensory complaints
and weakness. Nerve conduction studies abnormalities met
the criteria for axonal polyneuropathy. After a second SCT
with the original stem cell harvest, weakness and sensory
deficits did not deteriorate any further.
Patient 2 was diagnosed with MM, an IgA-lambda
gammopathy, and had a sensorimotor axonal polyneurop-
athy, with muscle atrophy, weakness, hypesthesia and
paresthesia in both lower legs and mild weakness of the
intrinsic hand muscles. MM was first treated with two
cycles of intermediate dose melfalan. Autologous stem cell
transplantation was then performed after pre-treatment
with cyclophosphamide and total body irradiation. Muco-
sitis was the most important complication of SCT. SCT
was performed 1 year after diagnosis of the polyneuropa-
thy and 3 years after the first neuropathic complaints. After
transplantation MRC motor sum scores declined a further
four points to 128/140, while the sensory sum score
declined from 44 to 40 out of 56. Follow-up during 5 years
showed no further changes in neurological examination,
and nerve conduction studies did not show further
progression.
Patient 3 had MM, an IgG-kappa gammopathy and a
rapidly progressive sensorimotor polyneuropathy. Nerve
conduction studies met the criteria for axonal polyneu-
ropathy. Marked weakness was present distally in arms and
legs, together with sock-and-glove patterned hypesthesia
and sensory ataxia. Ambulation was lost during the diag-
nostic work-up. After three cycles of adriamycin/dexa-
methasone and two cycles of intermediate dose melfalan,
autologous stem cell transplantation 30 months after the
first manifestation of polyneuropathy seemed to stabilize
the disease course for the duration of 1 month, but
2 months after transplantation the polyneuropathy deteri-
orated and caused severe weakness of respiratory and
bulbar muscles. Three months after transplantation the
patient died of respiratory insufficiency.
Patient 4 had primary amyloidosis with light chain
gammopathy and progressive neuropathy with sensory
ataxia and autonomic dysfunction leading to impotence,
orthostatic hypotension, and loss of bowel and bladder
control. Nerve conduction studies met the criteria for
axonal polyneuropathy. He was also treated with adria-
mycin, dexamethasone and melfalan, followed by autolo-
gous stem cell transplantation. After SCT this patient
developed herpes labialis, fever and deep venous throm-
bosis. SCT led to a complete hematological response, and
marked improvement of the autonomic complaints,
regaining of bowel control and normalization of blood
pressure regulation, which allowed the patient to regain
independence in the activities of daily life. Nerve con-
duction studies did not change after transplantation, and
motor scores decreased slightly (from 140 to 137 out of
140), while the sensory sum score improved from 44 to 46
out of 56.
Patient 5 had a rapidly progressive sensory and motor
demyelinating neuropathy and an IgG monoclonal gam-
mopathy. She presented to the outpatient clinic with
distal weakness in both legs, areflexia, hypesthesia of the
fingers and lower legs, ataxia and very severe neuro-
pathic pain, which did not respond to adequate dosage of
either antidepressants or anticonvulsants registered for
neuropathic pain treatment. The nerve conduction studies
fulfilled the criteria for demyelination, and the diagnosis
of CIDP with IgG monoclonal gammopathy was made.
Despite repeated IVIg infusions, there was a severe
progression of the neuropathy (Rankin scale 3). Treat-
ment with high-dose dexamethasone and melfalan led to
a further exacerbation of the polyneuropathy. After
autologous stem cell transplantation, preceded by adria-
mycin/cyclophosphamide and melfalan cycles, no further
progression occurred and the neuropathic pain disap-
peared, although motor scores did not improve. SCT was
complicated by neutropenic fever.
Patient 6 had MM with IgD paraproteinaemia and a
polyneuropathy with painful paresthesia of the feet, mild
weakness of the M. extensor hallucis longus and intact
reflexes. Nerve conduction studies were consistent with an
axonal polyneuropathy. One year after the first sensory
complaints she underwent autologous SCT, primarily
aimed at the MM. SCT was complicated by herpes simplex
infection in the mouth, urinary tract infection and fluid
overload. SCT led to diminished neuropathic pain, but
motor, sensory sum scores and nerve conduction studies
did not improve after transplantation.
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Discussion
Here we report on the effect of stem cell transplantation on
neuropathy in our cohort of 225 patients with monoclonal
gammopathy and neuropathy. We retrospectively selected
and analyzed six patients from this cohort who underwent
SCT, primarily aimed at the malignancy underlying the
monoclonal gammopathy rather than at the neuropathy. In
only one patient, who received SCT for MM, did the pol-
yneuropathy improve objectively. In one other patient,
treated with SCT for primary amyloidosis, autonomic
symptoms improved subjectively, allowing him to regain
independence in the activities in daily life; in three other
patients the neuropathy was at best stable after SCT, with
further decline in motor function, but improvement in
reported pain and in one patient slight improvement in
sensory sum scores. However, one patient died after as a
complication of the SCT. These results suggest that SCT
halts progression in a minority of cases of polyneuropathy
associated with B-cell dyscrasias, but that concerns about
safety need to be addressed.
Efficacy of SCT for refractory polyneuropathy associ-
ated with B cell dyscrasia has not been studied systemati-
cally. Case reports have documented improvement after
SCT in some patients with CIDP (7 patients), POEMS (42
patients) [5–8] and most recently in four patients with
MGUS associated neuropathy [10], but publication bias
may have precluded reports of cases with an unfavorable
outcome. SCT results ranged from complete remission of
the neuropathy in some POEMS and CIDP patients to full
relapse after initial improvement, and unresponsiveness to
SCT. In comparison to the patients described in previous
studies, all our patients but two had an axonal polyneu-
ropathy. This may explain the relative lack of beneficial
effect of stem cell transplantation in our group compared to
the recent publication of SCT for MGUS associated neu-
ropathy, as all patients in that study had a demyelinating
neuropathy.
The potentially beneficial effect of stem cell transplan-
tation needs to be carefully weighed against the consider-
able risks of treatment-related mortality and morbidity. The
European Group for Blood and Marrow Transplantation
(EBMT) registry has reported transplantation-related mor-
tality in 5% of 900 patients with autoimmune disease
between 1995 and 2007, with mortality clearly improving
in the years covered by the registry [14]. The treatment
center and the underlying disease may also represent
determinants of mortality due to SCT complications. In a
recent study, 2 out of 13 patients (15%) with AL amyloi-
dosis and autonomic neuropathy died within a 100 days
after transplantation and were considered transplantation-
related deaths [9]. Results from more studies are needed to
document whether SCT for B cell dyscrasias associated
with polyneuropathy carries a greater than average risk for
complications and death. The case history of patient 3
emphasizes that the natural disease course of some B
cell dyscrasia-associated neuropathies is relentless,
which justifies treatment strategies with a higher risk for
complications.
Due to the small number of patients with B cell dys-
crasia associated neuropathy who underwent SCT, we
could not establish an association between efficacy of SCT
and the underlying hematological disease. The case history
of patient 5 confirms findings from previous studies that
autologous SCT can be considered as treatment of last
resort in patients with CIDP and an associated monoclonal
gammopathy, even if the B cell dyscrasia by itself does not
warrant such treatment. Unfortunately, clinical trials
establishing whether and when autologous stem cell
transplantation should be considered are probably not
feasible due to the small numbers of eligible patients.
Standardized criteria of efficacy and detailed descriptions
of patients treated with SCT may help to clarify whether
specific nerve conduction features (i.e., demyelination,
axonal loss) or underlying hematological disorder may
predict outcome.
In conclusion, SCT might be considered as a treatment
of last resort in very severe, progressive and therapy-
resistant polyneuropathies associated with B cell dyscra-
sias. Nevertheless, the treatment-related mortality and
morbidity and the relatively high chance of a limited
response at best necessitate a careful and critical weighing
of risks and benefits in each individual patient, and treat-
ment should be limited to centers that have extensive
experience with SCT and very low mortality rates.
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